Syndax Pharmaceuticals Inc (SNDX)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Syndax Pharmaceuticals Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 8 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 19.20 $ — 60% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/04/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AAQS
5/10The AAQS (AlleAktien Quality Score) checks 10 quality criteria on growth, profitability, and balance-sheet strength — per the methodology developed and published by AlleAktien, calculated by us from our own fundamental data. A stock counts as a quality stock from 9 out of 10 points. Where a company has a shorter listing history, we calculate over the fiscal years available (at least five).
- Sales growth 10Y > 5% 73.3%
- Exp. sales growth 3Y > 5% 71.0%
- EBIT growth 10Y > 5% –
- Exp. EBIT growth 3Y > 5% 71.0%
- Net debt < 4x EBIT –
- EBIT positive, 10Y straight 1
- Max. EBIT decline < 50% 100.0%
- Return on equity > 15% -441.6%
- ROCE > 15% -66.7%
- Expected return > 10% 38.9%
View all AAQS quality stocks · Read the methodology at AlleAktien
Source: fundamental data
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Growth Score
4 of 10 Weak growthTen checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years 10.8% failed
- More than 10% revenue growth is expected for the coming year 45.9% passed
- Share count grows by less than 3% a year 12.6% failed
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") 440.3% passed
- Gross margin at 40% or higher and without meaningful erosion no data
- Goodwill from acquisitions does not grow faster than revenue 0.0% passed
- Net debt below twice EBITDA 67 m net cash passed
- Operating cash flow covers the profits of the last three years 55 m failed
- Return on capital at 15% or higher, or up versus two years ago -66.7% failed
- Insiders hold at least 10% or are net buyers 1.7% failed
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 105.5% above the current price.
- Consensus
- Strong Sell
- Analyst Ratings
- 12
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | -1.60 | -2.20 – -1.16 | 345 | 51.3% | 11 |
| 12/31/2027 | -0.36 | -1.32 – 0.43 | 504 | 77.3% | 11 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- -0.45 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -1.10 | – | 8 | 1,332.80 | -1,226.20 | -57 | -57 |
| 2025: Q1 | -0.99 | – | 20 | – | -423.30 | -95 | -95 |
| 2025: Q2 | -0.83 | – | 38 | 984.50 | -189.30 | -88 | -88 |
| 2025: Q3 | -0.70 | – | 46 | 267.00 | -132.40 | -71 | -71 |
| 2025: Q4 | -0.79 | – | 69 | 791.70 | -99.30 | -70 | -70 |
| 2026: Q1 | -0.49 | – | 65 | 223.60 | -65.80 | -50 | -50 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 1 | -44 | -44 | -3.04 | -35 | 84 | 109 |
| 2017 | 2 | -62 | -61 | -2.90 | -47 | 104 | 137 |
| 2018 | 2 | -76 | -74 | -2.92 | -69 | 53 | 84 |
| 2019 | 2 | -58 | -56 | -1.84 | -51 | 32 | 64 |
| 2020 | 2 | -71 | -73 | -1.77 | -71 | 252 | 301 |
| 2021 | 140 | 26 | 25 | 0.48 | 29 | 408 | 450 |
| 2022 | 127 | -152 | -144 | -2.37 | -134 | 467 | 497 |
| 2023 | 0 | -230 | -209 | -2.98 | -161 | 554 | 613 |
| 2024 | 24 | -340 | -319 | -3.72 | -275 | 288 | 725 |
| 2025 | 172 | -273 | -285 | -3.29 | -323 | 65 | 530 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Syndax Pharmaceuticals, Inc., ein biopharmazeutisches Unternehmen in der Vermarktungsphase, entwickelt Therapien zur Krebsbehandlung.
| CEO Insider Trades (12 Mo.) | selling own stock |
|---|---|
| Employees | 298 |
| Headquarters | New York, NY |
| Address | 730 Third Avenue, 10017 New York, United States |
| Phone | 781 419 1400 |
| Website | syndax.com |
| IPO Date | 3. Mar 2016 |
| ISIN | US87164F1057 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Michael A. Metzger M.B.A. | CEO & Director | 1971 |
| Keith Alan Goldan CPA | CFO, Treasurer & Principal Accounting Officer | 1971 |
| Luke J. Albrecht J.D. | Senior VP, General Counsel & Secretary | 1979 |
| Steven Closter | Chief Commercial Officer | 1969 |
| Nicholas A.J. Botwood B.Sc., MBBS | Head of Research & Development and Chief Medical Officer | 1968 |
| Peter Ordentlich B.Sc., Ph.D. | Co-Founder & Chief Scientific Officer | 1969 |
| Richard A. Heyman Ph.D. | Co-Founder | 1957 |
| Ronald M. Evans Ph.D. | Co-Founder, Advisor and Chair of Scientific Advisory Board | 1950 |
| Michael Downes Ph.D. | Co-Founder | – |
| Sharon Klahre | Vice President of Investor Relations & Communications | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 8. Jul 2026 | Metzger Michael A | Chief Executive Officer | Sell | 32,375 | 24.24 | 784,776 |
| 8. Jul 2026 | Metzger Michael A | Chief Executive Officer | Other | 32,375 | 6.38 | 206,553 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
View all insider transactions →Chart
Interactive price chart (TradingView).
Data as of: August 3, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.